Banner for news Banner for news


Generic contraceptive implant is now available in the UNFPA catalog

The Levonorgestrel 75 mg two-rod subdermal implant, marketed under the global brand name Levoplant, received a Risk Category 1 rating from the UNFPA/WHO Expert Review Panel (ERP). The procurement contract is finalized and the product has been added to the UNFPA catalog and is open for procurement.

UNFPA is committed to expanding the choice of quality assured generic contraceptives available to UNFPA programs, Member States and clients while delivering the best value for money.